Therapeutics News and Research

RSS

Innovative compound with anti-MRSA qualities may help develop new class of antibiotics

With global health services increasingly worried about the rise of antibiotic resistant diseases, researchers at Maynooth University have discovered a compound whose anti-MRSA qualities pave the way for the development of a new class of antibiotics.

1 Dec 2015

Scientists can accurately measure microbial growth rates inside gastrointestinal tracts

For the first time, scientists can accurately measure population growth rates of the microbes that live inside mammalian gastrointestinal tracts, according to a new method reported in Nature Communications by a team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School.

1 Dec 2015

Heptares announces strategic drug discovery collaboration with Pfizer

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas.

30 Nov 2015

Green Cross' GCFlu Quadrivalent approved to protect against four influenza strains in South Korea

Green Cross Corporation, a South Korean biopharmaceutical company, announced today that South Korea's Ministry of Food and Drug Safety has approved GCFLU QUADRIVALENT (Influenza Virus Vaccine) for immunisation of adults to help prevent disease caused by seasonal influenza (flu) virus subtype A and B. GCFlu Quadrivalent is the first locally-manufactured vaccine to cover against four influenza strains.

26 Nov 2015

Novel anticancer agent appears to have greater potency, longer efficacy than irinotecan and topotecan

In the five decades since camptothecin was first isolated from the bark of a tree used in traditional Chinese medicine and identified as a powerful anticancer agent, several thousand chemicals with similar structures and functions have been investigated. And while two of these analog compounds, irinotecan and topotecan, have been approved in the U.S. as treatments for cancer, both are associated with significant shortcomings.

26 Nov 2015

New research could lead to improved methods of detection for early-onset Parkinson's

New research by biologists at the University of York could lead to improved methods of detection for early-onset Parkinson's Disease (PD).

25 Nov 2015

Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

Allergan plc, a leading global pharmaceutical company, and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative, today announced that they have entered into an exclusive collaboration to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).

25 Nov 2015

BioLight signs joint financing agreement with two Asia-based venture capital firms

BioLight Life Sciences Investments, a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, announced today that it has entered into a joint financing agreement (the "Agreement") with two Asia-based venture capital firms (the "New Investors"), pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight's IOPtima Ltd. subsidiary via a private placement.

25 Nov 2015

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Impax Laboratories, Inc. today announced that the European Commission has granted marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease.

25 Nov 2015

Scientists create detailed image of deadly toxin linked to bacterial pneumonia, meningitis, septicaemia

Scientists from the University of Leicester have for the first time created a detailed image of a toxin - called pneumolysin - associated with deadly infections such as bacterial pneumonia, meningitis and septicaemia.

25 Nov 2015

T1DM therapeutics market expected to reach $7.1 billion by 2021

Analysis from business intelligence provider GBI Research - Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - states that the global market value for T1DM treatment will rise from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 7.9%.

24 Nov 2015

Impax releases generic version of dutasteride capsules, 0.5 mg

Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg.

24 Nov 2015

Green Cross' Biologics License Application for IVIG-SN submitted to FDA

Green Cross Corporation, a South Korean biopharmaceutical company, today announced that it has submitted its Biologics License Application for IVIG-SN (human normal immunoglobulin G for intravenous administration) to the United States Food and Drug Administration.

24 Nov 2015

Findings could offer doctors new method to diagnose pancreatic cancer earlier in patients

By collecting samples from the portal vein--which carries blood from the gastrointestinal tract, including from the pancreas, to the liver--physicians can learn far more about a patient's pancreatic cancer than by relying on peripheral blood from a more easily accessed vein in the arm.

23 Nov 2015

CRISPR tool unlocks potential for novel treatments across different therapeutic areas

CRISPR is one of the most exciting advances in gene-based medicine in decades. A uniquely powerful tool for editing the genome, it allows scientists to manipulate DNA with unprecedented precision by deleting unwanted or faulty genes and replacing them with different ones. Its promise in this field of medicine is immense, unlocking the potential for novel treatments across a wide range of therapeutic areas.

22 Nov 2015

Crucial tumor-suppressing gene protects immune attack against lung cancer

A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

21 Nov 2015

Innovative microbiome technology may help fight certain infections

Stony Brook University and Ortek Therapeutics, Inc. announced today that two patent applications were filed in the United States and internationally for nutrient based compositions utilizing an innovative microbiome technology that may help combat certain infections.

20 Nov 2015

New nanocarriers may effectively deliver therapeutic drug to GBM tumors

Glioblastoma multiforme, a cancer of the brain also known as "octopus tumors" because of the manner in which the cancer cells extend their tendrils into surrounding tissue, is virtually inoperable, resistant to therapies, and always fatal, usually within 15 months of onset.

20 Nov 2015

ProMetic, ProThera form strategic partnership to develop and commercialize Inter-alpha Inhibitor Proteins

ProMetic Life Sciences Inc. announced today that it has entered into a strategic partnership with ProThera Biologics Inc. for the development and commercialization of human plasma-derived Inter-alpha Inhibitor Proteins.

19 Nov 2015

International task force aims to develop new approach to cancer prevention and treatment

Advancements in precision medicine have led to many new targeted cancer therapies for cancer patients. These treatments focus on using agents that target one or two genes that contribute to tumor development. The approach tends to be more effective against cancer cells and less toxic toward normal cells than standard chemotherapeutic regimens.

19 Nov 2015

Therapeutics News and Research

Innovative compound with anti-MRSA qualities may help develop new class of antibiotics

Scientists can accurately measure microbial growth rates inside gastrointestinal tracts

Heptares announces strategic drug discovery collaboration with Pfizer

Green Cross' GCFlu Quadrivalent approved to protect against four influenza strains in South Korea

Novel anticancer agent appears to have greater potency, longer efficacy than irinotecan and topotecan

New research could lead to improved methods of detection for early-onset Parkinson's

Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

BioLight signs joint financing agreement with two Asia-based venture capital firms

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Scientists create detailed image of deadly toxin linked to bacterial pneumonia, meningitis, septicaemia

T1DM therapeutics market expected to reach $7.1 billion by 2021

Impax releases generic version of dutasteride capsules, 0.5 mg

Green Cross' Biologics License Application for IVIG-SN submitted to FDA

Findings could offer doctors new method to diagnose pancreatic cancer earlier in patients

CRISPR tool unlocks potential for novel treatments across different therapeutic areas

Crucial tumor-suppressing gene protects immune attack against lung cancer

Innovative microbiome technology may help fight certain infections

New nanocarriers may effectively deliver therapeutic drug to GBM tumors

ProMetic, ProThera form strategic partnership to develop and commercialize Inter-alpha Inhibitor Proteins

International task force aims to develop new approach to cancer prevention and treatment

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News